-
Innovation Ranking
NewInnovation Ranking – Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company that manufactures and supplies generic pharmaceutical products. The company's product portfolio includes oral solids, oncology OSD, general and oncology injectables, generic formulations, and ophthalmic and dermatology products. It offers products for various therapy areas such as cardiovascular, analgesics, genecology, cough and cold, gastroenterology, ophthalmology, anti-diabetics, orthopedic, urology and dermatological therapies. API company operates manufacturing facilities in Gujarat and Sikkim, India and research centers in Vadodara and Hyderabad, India and New Jersey, the...
-
Company Insights
Innovation and Patenting activity of Alembic Pharmaceuticals Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Alembic Pharmaceuticals Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Alembic Pharmaceuticals Ltd – Company Profile
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company that manufactures and supplies generic pharmaceutical products. The company's product portfolio includes oral solids, oncology OSD, general and oncology injectables, generic formulations, and ophthalmic and dermatology products. It offers products for therapeutic areas of cardiovascular, analgesics, gynecology, cough and cold, gastroenterology, ophthalmology, anti-diabetics, orthopedic, urology and dermatological therapies. The company operates India, the US, Canada, Brazil, Australia and South Africa. APL is headquartered in Vadodara, Gujarat, India.
Add to Basket -
Track & Monitor
Immuno-oncology in Pharmaceuticals: Alpha-cinnamide compositions for cancer
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
Chemotherapy in Pharmaceuticals: Purine derivatives-based cancer drug compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Track & Monitor
Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition
This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry.